Alaunos Therapeutics, Inc. 8-K

What Happened Alaunos Therapeutics, Inc. announced in an 8‑K filed April 15, 2026 that on April 9, 2026 it received a notice from the Nasdaq Listing Qualifications Department informing the company it does not meet Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market. The company’s 2025 Form 10‑K reported stockholders’ equity of $2,153,000. Alaunos said it will submit a plan to Nasdaq within the required 45 days and is evaluating actions to regain compliance.

Key Details

• Reported stockholders’ equity (FY ended Dec 31, 2025): $2,153,000 (below the $2,500,000 minimum).
• Nasdaq rule cited: Listing Rule 5550(b)(1).
• Deadline to submit compliance plan: 45 days from the notice (until May 26, 2026); Nasdaq may grant up to a 180‑day extension if the plan is accepted.
• Company does not meet alternative standards (market value of listed securities of $35M or net income of $500K in the most recent year or two of the last three).

Why It Matters This notice signals a potential delisting risk because Alaunos currently falls below Nasdaq’s minimum equity listing standard. For investors, that means the company must successfully persuade Nasdaq it can regain and sustain compliance (or secure an extension) or face delisting procedures. Trading is expected to continue while the company pursues its plan and, if necessary, requests a hearing, but there is no assurance the plan will be accepted or that the company will regain compliance.